Experimental Arm for Obesity

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Robert Wood Johnson University Hospital, New Brunswick, NJ
Obesity+3 More
NBT-NM108 - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This study aims to use a high-fiber supplementation, an intervention known to create shifts in the gut microbiota towards a healthier structure, to explore the relationship between gut microbiota, appetite control and feeding behavior in PWS patients.

Eligible Conditions

  • Obesity
  • Royer Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Week 4

Week 4
24 hour dietary recall
Functional MRI
Ghrelin level
Glucose level
Gut microbiota composition
Hyperphagia questionnaire
Insulin level
Weight

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Experimental Arm
1 of 1
Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Experimental Arm · No Placebo Group · Phase 2

Experimental Arm
Drug
Experimental Group · 1 Intervention: NBT-NM108 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week 4

Trial Background

Prof. Keerthana Kesavarapu D.O., Assistant Professor
Principal Investigator
Rutgers, The State University of New Jersey
Closest Location: Robert Wood Johnson University Hospital · New Brunswick, NJ
2004First Recorded Clinical Trial
2 TrialsResearching Obesity
43 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References